After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT),
this therapy has advanced from one that was declared dead in the 1960s to a standard …

Acute graft-vs-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic
stem cell transplantation (HSCT), leading to a significant morbidity and mortality. GVHD …

Because of its potent immunosuppressive yet stem cell–sparing activity, high-dose
cyclophosphamide was tested as sole prophylaxis of graft-versus-host disease (GVHD) after …

Patients successfully treated with a marrow transplant often have concerns about fertility and
pregnancy. This study was performed to determine pregnancy outcome among patients who …

We have reviewed results of therapy in 740 patients with grades II-IV acute graft-versus-host
disease (GVHD) after allogeneic marrow transplantation. At the beginning of therapy, 597 …

We report the results of a phase III open-label, randomized, multicenter trial comparing
tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) …

In patients with alpha1-antitrypsin deficiency, the development of emphysema is believed to
be caused by the unchecked action of proteases on lung tissue. We evaluated the feasibility …

After the transplantation of unmodified marrow from human leukocyte antigen-matched
unrelated donors receiving cyclosporine (CSP) and methotrexate (MTX), the incidence of …

CD28 is a homodimeric glycoprotein expressed on the surface of a major subset of human T
cells that has recently been identified as a member of the immunoglobulin supergene family …

Abstract Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of
matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) …